Health Condition 1: L649- Androgenic alopecia, unspecified
Conditions
Interventions
Intervention1: Topical Minoxidil 5%: Cetosomal Minoxidil
1 ml of Minoxidil 5% solution Twice daily for 16 weeks
Control Intervention1: Topical Minoxidil 5%: Conventional Minoxidil
1 ml of Minoxidil
Sponsors
Hairrevive Centre for Hair Restoration Skin Rejuvenation
Eligibility
Inclusion criteria
Inclusion criteria: Adult male patients of PHL of mild-moderate severity (BASP grading) Patients willing to refrain from other forms of treatment including other topical, oral medication for hair loss, laser treatments, injectable treatments and hair transplantation for the duration of study Patients who are willing to appear for regular follow ups and follow the prescribed treatment regularly Patients who are willing to give consent to participate in the study
Exclusion criteria
Exclusion criteria: 1. Patients suffering from other causes of non-cicatricial alopecia or cicatricial alopecia. 2. Patients suffering from infectious, auto-immune, or other disorders affecting skin of scalp. 3. Patients suffering from severe PHL, BASP scale M3, C2, C3, U1, U2, U3, V2, V3, F2, and F3 were recorded as â??severeâ?? and excluded from the study. 4. Documented and known history of severe systemic disease, necessitating medical treatment, as assessed by the Investigator that might interfere with the conduct of the study or the interpretation of results. 5. Patients known to be allergic to the any of the components of the study medications. 6. Patients who are receiving drugs which are known to affect hair growth. 7. Patients with known malignancy. 8. Refusal to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison in proportion of patients showing one or more adverse effects or change in the parameters of local skin tolerability (erythema, dryness, hyperpigmentation, skin peeling, pruritus) from baseline, with Cetosomal vs. Conventional Minoxidil 5% solutionTimepoint: upto 16 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparison of percentage change in Trichoscopy score at week 16 versus baseline in both groups 2. Comparison of proportion of patients showing improvement on Trichoscopic evaluation at week 16 versus baseline in both groups 3. Comparison of proportion of patient showing improvement in BASP grading (physician recorded) at week 16 versus baseline in both groups. 4. Comparison in proportion of patients showing improvement in clinical photographs at week 16 vs. those taken at baseline 5. Comparison of percentage improvement in mean score of Hairdex-29 scale at week 16 compared to baseline. Timepoint: upto 16 weeks | — |
Countries
India
Contacts
Public ContactDr Sandeep Sattur
Hairrevive Centre for Hair Restoration & Skin
Outcome results
None listed